Cargando…

Erratum: Case report: PTEN mutation induced by anti-PD-1 therapy in stage IV lung adenocarcinoma

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632993/ https://www.ncbi.nlm.nih.gov/pubmed/36339554 http://dx.doi.org/10.3389/fphar.2022.1058178

Ejemplares similares

Case Report: PTEN Mutation Induced by anti-PD-1 Therapy in Stage IV Lung Adenocarcinoma
por: Teng, Junjie, et al.
Publicado: (2022)

Case Report: Stevens-Johnson Syndrome and Hepatotoxicity Induced by Osimertinib Sequential to Pembrolizumab in a Patient With EGFR-Mutated Lung Adenocarcinoma
por: Gianni, Caterina, et al.
Publicado: (2021)

Radiation-induced sarcoma in a 10-year survivor with stage IV EGFR-mutated lung adenocarcinoma
por: Shibahara, Daisuke, et al.
Publicado: (2019)

Identification of Mutations Related to Cisplatin-Resistance and Prognosis of Patients With Lung Adenocarcinoma
por: Li, Rui, et al.
Publicado: (2020)

Case report: ALK D1225N missense mutation in lung adenocarcinoma responds to tyrosine kinase inhibitors
por: Chen, Jianxin, et al.
Publicado: (2023)

Impact of Cytological Sampling on EGFR Mutation Testing in Stage III-IV Lung Adenocarcinoma
por: Davies, Rhian Siân, et al.
Publicado: (2017)

Impact of Radiotherapy Pattern on the Prognosis of Stage IV Lung Adenocarcinomas Harboring EGFR Mutations
por: Zhang, Yingyun, et al.
Publicado: (2021)

Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint Inhibitors
por: Niu, Yuchun, et al.
Publicado: (2020)

Anti-Proliferative and Apoptosis-Inducing Effect of Theabrownin against Non-small Cell Lung Adenocarcinoma A549 Cells
por: Wu, Feifei, et al.
Publicado: (2016)

Immune mediators as predictive biomarkers for anti-PD-1 antibody therapy in urothelial carcinoma
por: Shibata, Yosuke, et al.
Publicado: (2023)

Pexidartinib synergize PD-1 antibody through inhibiting treg infiltration by reducing TAM-derived CCL22 in lung adenocarcinoma
por: Zhang, Wei, et al.
Publicado: (2023)

Case Report: Successful Avatrombopag Treatment for Two Cases of Anti-PD-1 Antibody-Induced Acquired Amegakaryocytic Thrombocytopenia
por: Tu, Xiaofang, et al.
Publicado: (2022)

Cinobufagin Is a Selective Anti-Cancer Agent against Tumors with EGFR Amplification and PTEN Deletion
por: He, Kunyan, et al.
Publicado: (2021)

SOX chemotherapy with anti-PD-1 and iNKT cell immunotherapies for stage IV gastric adenocarcinoma with liver metastases: A case report
por: Li, Dezhao, et al.
Publicado: (2022)

Stage IV EGFR Mutation-Negative and ALK Mutation-Negative Lung Adenocarcinoma: Long-Term Survival is Possible
por: Kedia, Shiksha, et al.
Publicado: (2015)

Adaptive NK Cell Therapy Modulated by Anti-PD-1 Antibody in Gastric Cancer Model
por: Abdolahi, Shahrokh, et al.
Publicado: (2021)

Concurrent EGFR mutation and ALK rearrangement in stage IV lung adenocarcinoma—a case report and a literature review
por: Cipriano, Élia, et al.
Publicado: (2021)

Persistent response of furmonertinib plus anlotinib in a lung adenocarcinoma patient with an EGFR exon 20 insertion mutation: A case report
por: Chen, Xuesong, et al.
Publicado: (2023)

Anti-PD-1 Immunotherapy and Radiotherapy for Stage IV Intrahepatic Cholangiocarcinoma: A Case Report
por: Liu, Ze-Long, et al.
Publicado: (2020)

Kanglaite Combined With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy for Stage III/IV Non-Small Cell Lung Cancer: A PRISMA-Compliant Meta-Analysis
por: Kong, Fanming, et al.
Publicado: (2021)

Qingfei Jiedu decoction inhibits PD-L1 expression in lung adenocarcinoma based on network pharmacology analysis, molecular docking and experimental verification
por: Pan, Junjie, et al.
Publicado: (2022)

Case report: Clinical management of recurrent small cell lung cancer transformation complicated with lung cancer-induced acute pancreatitis after lung adenocarcinoma surgery
por: Zhang, Suyun, et al.
Publicado: (2023)

Comprehensive Evaluation of Anti-PD-1, Anti-PD-L1, Anti-CTLA-4 and Their Combined Immunotherapy in Clinical Trials: A Systematic Review and Meta-analysis
por: Xiang, Ze, et al.
Publicado: (2022)

Case Report: A Case Report and Literature Review on Severe Bullous Skin Reaction Induced by anti-PD-1 Immunotherapy in a Cervical Cancer Patient
por: Li, Xiang, et al.
Publicado: (2021)

Prognostic Significance of PD-L1 Expression and Standardized Uptake Values in the Primary Lesions of Stage IV Adenocarcinoma Lung Cancer
por: Tien Cong, Bui, et al.
Publicado: (2022)

Anti-PD-L1 immunoconjugates for cancer therapy: Are available antibodies good carriers for toxic payload delivering?
por: Zanello, Andrea, et al.
Publicado: (2022)

Cost-Utility Analysis of Lipegfilgrastim Compared to Pegfilgrastim for the Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Stage II-IV Breast Cancer
por: Akpo, Esse I. H., et al.
Publicado: (2017)

Catenin Alpha-2 Mutation Changes the Immune Microenvironment in Lung Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitors
por: Wen, Yang, et al.
Publicado: (2021)

Efficacy and Safety of Anti-PD-1/ PD-L1 Monotherapy for Metastatic Breast Cancer: Clinical Evidence
por: Qi, Yihang, et al.
Publicado: (2021)

NCS 613, a Potent PDE4 Inhibitor, Displays Anti-Inflammatory and Anti-Proliferative Properties on A549 Lung Epithelial Cells and Human Lung Adenocarcinoma Explants
por: Yougbare, Issaka, et al.
Publicado: (2020)

PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake
por: Zhang, Jian-ye, et al.
Publicado: (2020)

Significant metabolic alterations in non-small cell lung cancer patients by epidermal growth factor receptor-targeted therapy and PD-1/PD-L1 immunotherapy
por: Yan, Chen, et al.
Publicado: (2022)

Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives
por: Zhao, Yating, et al.
Publicado: (2021)

Autophagy Inhibition Enhances the Anti-Tumor Activity of Methylseleninic Acid in Cisplatin-Resistance Human Lung Adenocarcinoma Cells
por: Xin, Ming, et al.
Publicado: (2022)

Hesperetin Promotes Cisplatin−Induced Apoptosis of Gastric Cancer In Vitro and In Vivo by Upregulating PTEN Expression
por: He, Pengzhan, et al.
Publicado: (2020)

A systematic and comprehensive analysis of T cell exhaustion related to therapy in lung adenocarcinoma tumor microenvironment
por: Hu, Peipei, et al.
Publicado: (2023)

Case Report: ALK rearranged locally advanced lung adenocarcinoma showing inconsistent radiographic findings and pathological responses during neoadjuvant alectinib therapy
por: Cao, Peijun, et al.
Publicado: (2023)

Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis
por: Wang, Peng-Fei, et al.
Publicado: (2017)

Anti-PD-1/PD-L1 for nasopharyngeal carcinoma: a comprehensive analysis of registered trials on ClinicalTrials.gov
por: Dai, Zelei, et al.
Publicado: (2023)

Fatal Tumour Lysis Syndrome Induced by Brigatinib in a Lung Adenocarcinoma Patient Treated With Sequential ALK Inhibitors: A Case Report
por: Wang, Yadong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_r4qtejlm4p2im0g3ahr2facnnv